In Vivo CAR Therapies Report
Over the last few years In Vivo CAR Therapies have been increasing in popularity as a potential treatment for various cancer indications and auto-immune diseases.
The lower manufacturing costs of this exciting new modality, in comparison to ex vivo CAR T-cell therapies, make in vivo CAR therapies an attractive prospect for drug developers.
With exclusive data from Beacon, this review contains:
- An overview of the in vivo CAR Therapy landscape and the therapies currently clinically active
- A look at the potential delivery systems and disease indications for in vivo CAR therapies
- An outline of the collaborations and financial deals in the in vivo CAR therapy space.
You May Also Be Interested In…
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
